Tissue factor in cancer and angiogenesis: The molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 1, 2006, Pages 54-69

  Rak, Janusz ^a,b   Milsom, Chloe ^b   May, Linda ^b   Klement, Petr ^b,c   Yu, Joanne ^b  

^a HENDERSON RESEARCH CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

Author keywords

Angiogenesis; Cancer; Oncogenes; Tissue factor; Tumor suppressors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR; GEFITINIB; IMATINIB; K RAS PROTEIN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR B; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR; SEMAXANIB; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOPLASTIN; THROMBOSPONDIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING DISORDER; CANCER; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HYPERCOAGULABILITY; METASTASIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM;

EID: 33644543744     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-933341     Document Type: Review

References (168)

1. Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumor cells and endothelial cells. The "angiogenesis progression" hypothesis. Eur J Cancer 1996;32A:2438-2450
2. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-379
3. Folkman J, Kalluri R. Tumor angiogenesis. In: Cancer Medicine. Kufe DW, Pollock RE, Weichselbaum RR, et al, eds. Hamilton, Canada: BC Decker, 2003:161-194
4. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris. The Sydenham Society 2nd; 1865:654-712. Paris, France. Serial (book, monograph)
5. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003;124:58S-68S
6. Dvorak FH. Abnormalities of hemostasis in malignant disease. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Coleman RB, Hirsh J, Marder VJ, Salzman JB, eds. Philadelphia, PA: Lippincott; 1994:1238-1254
7. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 2005;31:104-110
8. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395
9. Rak J, Kerbel RS. Oncogenes and tumor angiogenesis. In: Oncogene-Directed Therapies Rak J, ed. Totowa, NJ: Humana Press; 2003:171-218
10. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003;3:411-421
11. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997;277:48-50
12. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248
13. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257
14. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161:1163-1177
15. Folkman J. Endogenous angiogenesis inhibitors. Acta Path Microbiol Scand 2004;112:496-507
16. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52
17. Pettersson A, Nagy JA, Brown LF, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000;80:99-115
18. Dvorak HF, Orenstein NS, Carvalho AC, et al. Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor secreted products. J Immunol 1979;122:166-174
19. Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost 2004;30:31-44
20. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-835
21. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-1998
22. Ruf W, Seftor EA, Petrovan RJ, et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 2003;63:5381-5389
23. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996;69:135-174
24. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000;275:1521-1524
25. Folkman J. Angiogenesis and proteins of the hemostatic system. J Thromb Haemost 2003;1:1681-1682
26. Kalluri R. Basement membranes: structure assembly and role in tumor angiogenesis. Nat Rev Cancer 2003;3:422-433
27. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001;33:357-369
28. Kwak C, Jin RJ, Lee C, Park MS, Lee SE. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 2002;89:303-309
29. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611
30. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002;1:219-227
31. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442
32. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-439
33. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002;1:193-202
34. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999;59:1592-1598
35. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
36. Viloria-Petit A, Miquerol L, Yu JL, et al. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J 2003;22:4091-4102
37. Duarte A, Hirashima M, Benedito R, et al. Dosage-sensitive requirement for mouse D114 in artery development. Genes Dev 2004;18:2474-2478
38. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998;93:741-753
39. Pola R, Ling LE, Silver M, et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 2001;7:706-711
40. Wang B, Xiao Y, Ding BB, et al. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 2003;4:19-29
41. Carmeliet P, Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. Nature 2005;436:193-200
42. Relf M, Lejeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-969
43. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000;35:71-103
44. Giaccia A. Genetic basis of altered responsiveness of cancer cells to their microenvironment. In: Oncogene-Directed Therapies. Rak J, ed. Totowa, NJ: Humana Press; 2003:113-132
45. Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000;5:24-33
46. Rastinejaol F, Polvesini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989;56:345-355
47. Done S, Squire JA. Genetic basis of cancer progression. In: Oncogene-Directed Therapies. Rak J., ed. Totowa, NJ: Humana Press; 2003:3-18
48. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767
49. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-1584
50. Rak J, St. Croix B, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995;6:3-18
51. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Sasazuki T, Kerbel RS. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-4580
52. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995;270:25915-25919
53. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996;56:3436-3440
54. Kalas W, Yu JL, Milsom C, et al. Oncogenes and angiogenesis. Downregulation of thrombospondin 1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res 2005;65:8878-8886
55. Rak J, Klement G. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev 2000;19:93-96
56. Yu JL, May L, Klement P, Weitz JI, Rak J. Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost 2004;30:21-30
57. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004;2:2065-2067
58. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005;105:1734-1741
59. Boccaccio C, Sabatino G, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005;434:396-400
60. Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005;65:1406-1413
61. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002;4:465-473
62. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004;24:1015-1022
63. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001;86:66-74
64. Levi M. Hemostasis in the 21st century. Neth J Med 1999;55:280-286
65. Kakkar AK. Thrombosis and cancer. Hematol J 2004;5(suppl 3):S20-S23
66. Nand S, Messmore H. Hemostasis in malignancy. Am J Hematol 1990;35:45-55
67. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001;3:371-384
68. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-407
69. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol 2001;106:6-12
70. Ma L, Francia G, Viloria-Petit A, et al. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 2005;65:5365-5373
71. Kuenen BC, Levi M, Meijers JC, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 2002;22:1500-1505
72. Prandoni P, Lensing AW, Büller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-1133
73. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209-215
74. Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998;152:399-411
75. Zacharski LR, Memoli VA, Costantini V, Wojtukiewicz MZ, Ornstein DL. Clotting factors in tumour tissue: implications for cancer therapy. Blood Coagul Fibrinolysis 1990;1:71-78
76. Jain RK. Normalizing tumor vaculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989
77. Wojtukiewicz MZ, Rucinska M, Zimnoch L, et al. Expression of prothrombin fragment 1 + 2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res 2000;97:335-342
78. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Indirect activation of blood coagulation in colon cancer. Thromb Haemost 1989;62:1062-1066
79. Zacharski LR, Memoli VA, Morain WD, Schlaeppi JM, Rousseau SM. Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding. Thromb Haemost 1995;73:793-797
80. Wojtukiewicz MZ, Rucinska M, Zacharski LR, et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 2001;86:1416-1420
81. Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004;84:397-405
82. Rauch U, Antoniak S, Boots M, et al. Association of tissue-factor upregulation in squamous-cell carcinoma of the lung with increased tissue factor in circulating blood. Lancet Oncol 2005;6:254
83. Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998;80:894-898
84. Seto S, Onodera H, Kaido T, et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000;88:295-301
85. Nakasaki T, Wada H, Shigemori C, et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002;69:247-254
86. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995;82:1101-1104
87. Nitori N, Ino Y, Nakanishi Y, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005;11:2531-2539
88. Akashi T, Furuya Y, Ohta S, Fuse H. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology 2003;62:1078-1082
89. Koomagi R, Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998;20(79):19-22
90. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 2003;1:1495-1503
91. Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ. Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med 2004;10:6-11
92. Versteeg HH, Peppelenbosch MP, Spek CA. Tissue factor signal transduction in angiogenesis. Carcinogenesis 2003;24:1009-1013
93. Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic systems. Int J Hematol 2004;79:103-108
94. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005;25:1545-1550
95. Gonzalez-Gronow M, Gawdi G, Pizzo SV. Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells. Blood 2002;99:4562-4567
96. Albrecht S, Magdolen V, Herzog U, et al. Soluble tissue factor interferes with angiostatin-mediated inhibition of endothelial cell proliferation by lysine-specific interaction with plasminogen kringle domains. Thromb Haemost 2002;88:1054-1059
97. Chen J, Bierhaus A, Schiekofer S, et al. Tissue factor-a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001;86:334-345
98. Wiiger MT, Prydz H. The epidermal growth factor receptor (EGFR) and proline rich tyrosine kinase 2 (PYK2) are involved in tissue factor dependent factor VIIa signalling in HaCaT cells. Thromb Haemost 2004;92:13-22
99. Siegbahn A, Johnell M, Sorensen BB, Petersen LC, Heldin CH. Regulation of chemotaxis by the cytoplasmic domain of tissue factor. Thromb Haemost 2005;93:27-34
100. Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998;140:1241-1253
101. Ott I, Weigand B, Michl R, et al. Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation 2005;111:349-355
102. Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96:8663-8668
103. Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999;82:88-92
104. Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10:502-509
105. Parry GC, Mackman N. Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain. J Clin Invest 2000;105:1547-1554
106. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-264
107. Steinhoff M, Buddenkotte J, Shpacovitch V, et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005;26:1-43
108. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996;383:73-75
109. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996;88:1583-1587
110. Bugge TH, Xiao Q, Kombrinck KW, et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA 1996;93:6258-6263
111. Rosen ED, Chan JC, Idusogie E, et al. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 1997;390:290-294
112. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science 2001;293:1666-1670
113. Ollivier V, Chabbat J, Herbert JM, Hakim J, de Prost D. Vascular endothelial growth factor production by fibroblasts in response to factor Vila binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol 2000;20:1374-1381
114. Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J Biol Chem 1999;274:23969-23976
115. Mechtcheriakova D, Schabbauer G, Lucerna M, et al. Specificity, diversity, and convergence in VEGF and TNF-{alpha} signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001;15:230-242
116. Lucerna M, Mechtcheriakova D, Kadi A, et al. NAB2, a corepressor of EGR-1, inhibits VEGF-mediated gene induction and angiogenic responses of endothelial cells. J Biol Chem 2003;278:11433-11440
117. Kim I, Oh JL, Ryu YS, et al. Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J 2002;16:126-128
118. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320-1327
119. Hjortoe GM, Petersen LC, Albrektsen T, et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004;103:3029-3037
120. Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 2000;275:6580-6585
121. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96:3302-3309
122. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002;62:6966-6972
123. Parry GC, Erlich JH, Carmeliet P, Luther T, Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest 1998;101:560-569
124. Ngo CV, Manning CA, McCabe F, Millar H, Nakada MT, Anderson GM. Combination antibody therapy targeting both xenograft- and host-derived tissue factor leads to potent tumor inhibition. Paper presented at: the American Association of Cancer Research 46 [abstract 548]; April 16-20, 2005; Anaheim, CA
125. Lykke J, Nielsen HJ. Haemostatic alterations in colorectal cancer: perspectives for future treatment. J Surg Oncol 2004;88:269-275
126. Wang X, Wang M, Amarzguioui M, Liu F, Fodstad O, Prydz H. Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int J Cancer 2004;112:994-1002
127. Hembrough TA, Swartz GM, Papathanassiu A, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003;63:2997-3000
128. Toomey JR, Kratzer KE, Lasky NM, Broze GJ Jr. Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci USA 1997;94:6922-6926
129. Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998;101:1372-1378
130. Denko NC, Giaccia AJ. Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res 2001;61:795-798
131. Yan SF, Zou YS, Gao Y, et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci USA 1998;95:8298-8303
132. Mackman N. Regulation of the tissue factor gene. Thromb Haemost 1997;78:747-754
133. Ishibashi H, Nakagawa K, Onimaru M, et al. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor betal, and tissue factor and also cell growth and invasion activities. Cancer Res 2000;60:6531-6536
134. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260:85-88
135. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-269
136. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526-1528
137. Nash GF, Walsh DC, Kakkar AK. The role of the coagulation system in tumour angiogenesis. Lancet Oncol 2001;2:608-613
138. Kaplan R, DeLa Cadena RA. Mechanism of the coagulopathy associated with acute promyelocytic leukemia-clinical conference. Am J Hematol 1998;59:234-237
139. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
140. Huang YQ, Li JJ, Karpatkin S. Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway. J Biol Chem 2000;275:6462-6468
141. Zain J, Huang YQ, Feng X, Nierodzik ML, Li JJ, Karpatkin S. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 2000;95:3133-3138
142. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997;89:2429-2442
143. Watson LM, Chan AK, Berry LR, et al. Overexpression of the 78-kDa glucose-regulated protein/immunoglobulin-binding protein (GRP78/BiP) inhibits tissue factor procoagulant activity. J Biol Chem 2003;278:17438-17447
144. Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC. Antiapoptotic effect of coagulation factor Vila. Blood 2003;102:1708-1715
145. Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 2004;23:410-417
146. Versteeg HH, Spek CA, Slofstra SH, Diks SH, Richel DJ, Peppelenbosch MP. FVIIa:TF induces cell survival via G12/G13-dependent Jak/STAT activation and BclXL production. Circ Res 2004;94:1032-1040
147. Lwaleed BA, Cooper AJ. Tissue factor expression and multi-drug resistance in cancer: two aspects of a common cellular response to a hostile milieu. Med Hypotheses 2000;55:470-473
148. Rak J, Kerbel RS. Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Cancer Metastasis Rev 1996;15:231-236
149. Rak J, Yu JL. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand" Semin Cancer Biol 2004;14:93-104
150. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-458
151. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992;89:11832-11836
152. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996;77:1877-1883
153. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995;92:8205-8209
154. Francis JL, Amirkhosravi A. Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 2002;28:29-38
155. Amirkhosravi A, Meyer T, Chang JY, et al. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002;87:930-936
156. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on rumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995;74:282-290
157. Im JH, Fu W, Wang H, et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004;64:8613-8619
158. Nierodzik ML, Chen K, Takeshita K, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998;92:3694-3700
159. Nierodzik M, Karpatkin S. Hypercoagulability preceding cancer. Does hypercoagulability awaken dormant tumor cells in the host? J Thromb Haemost 2005;3:577-580
160. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-550
161. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci USA 2001;98:12180-12185
162. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129
163. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135
164. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944-1948
165. Bachli E. History of tissue factor. Br J Haematol 2000;110:248-255
166. Prydz H, Camerer E, Rottingen JA, Wiiger MT, Gjernes E. Cellular consequences of the initiation of blood coagulation. Thromb Haemost 1999;82:183-192
167. Tallman MS, Lefevbre P, Baine RM et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of system blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004;2:1341-1350
168. Milsom C, Rak J. Regulation of tissue factor and angiogenesis-related genes by changes in cell shape. Biochem Biophys Res Commun 2005;337:1207-1275